Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 49

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells

Palsuledesai, Charuta C., Ochocki, Joshua D., Kuhns, Michelle M., Wang, Yen-Chih, Warmka, Janel K., Chernick, Dustin S., Wattenberg, Elizabeth V., Li, Ling, Arriaga, Edgar A., Distefano, Mark D. · 2016 · ACS Chemical Biology

Abstract

Protein prenylation is a post-translational modification that is responsible for membrane association and protein–protein interactions. The oncogenic protein Ras, which is prenylated, has been the subject of intense study in the past 20 years as a therapeutic target. Several studies have shown a correlation between neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease and protein prenylation. Here, a method for imaging and quantification of the prenylome using microscopy and flow cytometry is described. We show that metabolically incorporating an alkyne isoprenoid into mammalian cells, followed by a Cu(I)-catalyzed alkyne azide cycloaddition reaction to a fluorophore, allows for detection of prenylated proteins in several cell lines and that different cell types vary significantly in their levels of prenylated proteins. The addition of a prenyltransferase inhibitor or the precursors to the native isoprenoid substrates lowers the levels of labeled prenylated proteins. Finally, we demonstrate that there is a significantly higher (22%) level of prenylated proteins in a cellular model of compromised autophagy as compared to normal cells, supporting the hypothesis of a potential involvement of protein prenylation in abrogated autophagy. These results highlight the utility of total prenylome labeling for studies on the role of protein prenylation in various diseases including aging-related disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.6b00421

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 58

  1. Epstein, 1991, Quantitation of prenylcysteines by a selective cleavage reaction, Proc. Natl. Acad. Sci. U. S. A., 88, 9668, 10.1073/pnas.88.21.9668 · DOI
  2. Zhang, 1996, Protein prenylation: Molecular mechanisms and functional consequences, Annu. Rev. Biochem., 65, 241, 10.1146/annurev.bi.65.070196.001325 · DOI · Paper page
  3. Saxena, 2008, RAS: target for cancer therapy, Cancer Invest., 26, 948, 10.1080/07357900802087275 · DOI
  4. Agrawal, 2009, Farnesyltransferase inhibitor as anticancer agent, Mini-Rev. Med. Chem., 9, 638, 10.2174/138955709788452702 · DOI
  5. Brunner, 2003, Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations, Cancer Res., 63, 5656
  6. Konstantinopoulos, 2007, Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets, Nat. Rev. Drug Discovery, 6, 541, 10.1038/nrd2221 · DOI · Paper page
  7. Fletcher, 2008, Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation, J. Med. Chem., 51, 5176, 10.1021/jm800113p · DOI
  8. Kraus, 2010, Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery, J. Med. Chem., 53, 3887, 10.1021/jm9013136 · doi:10.1021/jm9013136
  9. Bordier, 2002, A prenylation inhibitor prevents production of infectious hepatitis delta virus particles, J. Virol., 76, 10465, 10.1128/JVI.76.20.10465-10472.2002 · DOI
  10. Liu, 2009, Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson’s disease, Proc. Natl. Acad. Sci. U. S. A., 106, 4635, 10.1073/pnas.0806474106 · DOI
  11. Eckert, 2009, Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients, Neurobiol. Dis., 35, 251, 10.1016/j.nbd.2009.05.005 · DOI · Paper page
  12. Hooff, 2010, A rapid and sensitive assay for determining human brain levels of farnesyl-(FPP) and geranylgeranylpyrophosphate (GGPP) and transferase activities using UHPLC-MS/MS, Anal. Bioanal. Chem., 398, 1801, 10.1007/s00216-010-4088-7 · DOI
  13. Hooff, 2008, Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP), Anal. Bioanal. Chem., 392, 673, 10.1007/s00216-008-2306-3 · DOI
  14. Mans, 2012, Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation, Neuroscience, 202, 1, 10.1016/j.neuroscience.2011.12.007 · DOI
  15. Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann. Neurol., 60, 729, 10.1002/ana.21053 · DOI
  16. Benetka, 2006, Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivo, BMC Biochem., 7, 6, 10.1186/1471-2091-7-6 · DOI
  17. Berndt, 2011, Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors, Nat. Protoc., 6, 1775, 10.1038/nprot.2011.387 · DOI
  18. Schmidt, 1984, Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins, J. Biol. Chem., 259, 10175, 10.1016/S0021-9258(18)90945-2 · DOI · Paper page
  19. Onono, 2013, Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells Is regulated independently of the mevalonate pathway, J. Biol. Chem., 288, 27444, 10.1074/jbc.M113.482307 · doi:10.1074/jbc.m113.482307
  20. Kho, 2004, A tagging-via-substrate technology for detection and proteomics of farnesylated proteins, Proc. Natl. Acad. Sci. U. S. A., 101, 12479, 10.1073/pnas.0403413101 · DOI · Paper page
  21. Berry, 2010, Rapid multilabel detection of geranylgeranylated proteins by using bioorthogonal ligation chemistry, ChemBioChem, 11, 771, 10.1002/cbic.201000087 · DOI
  22. DeGraw, 2010, Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation, Chem. Biol. Drug Des., 76, 460, 10.1111/j.1747-0285.2010.01037.x · DOI
  23. Charron, 2013, Prenylome profiling reveals S-farnesylation is crucial for membrane targeting and antiviral activity of ZAP long-isoform, Proc. Natl. Acad. Sci. U. S. A., 110, 11085, 10.1073/pnas.1302564110 · DOI
  24. Charron, 2011, Alkynyl-farnesol reporters for detection of protein S-prenylation in cells, Mol. BioSyst., 7, 67, 10.1039/C0MB00183J · DOI
  25. Chan, 2009, A novel approach to tag and identify geranylgeranylated proteins, Electrophoresis, 30, 3598, 10.1002/elps.200900259 · DOI
  26. Palsuledesai, 2014, A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins, Mol. BioSyst., 10, 1094, 10.1039/C3MB70593E · DOI
  27. Nguyen, 2009, Analysis of the eukaryotic prenylome by isoprenoid affinity tagging, Nat. Chem. Biol., 5, 227, 10.1038/nchembio.149 · DOI · Paper page
  28. Das, 2012, Flexible and general synthesis of functionalized phosphoisoprenoids for the study of prenylation in vivo and in vitro, ChemBioChem, 13, 674, 10.1002/cbic.201100733 · doi:10.1002/cbic.201100733
  29. Patterson, 2014, Finding the right (bioorthogonal) chemistry, ACS Chem. Biol., 9, 592, 10.1021/cb400828a · DOI · Paper page
  30. Speers, 2004, Profiling enzyme activities in vivo using click chemistry methods, Chem. Biol., 11, 535, 10.1016/j.chembiol.2004.03.012 · DOI · Paper page
  31. Duckworth, 2007, Selective labeling of proteins by using protein farnesyltransferase, ChemBioChem, 8, 98, 10.1002/cbic.200600340 · DOI
  32. Hosokawa, 2007, Evaluation of an alkyne-containing analogue of farnesyl diphosphate as a dual substrate for protein-prenyltransferases, Int. J. Pept. Res. Ther., 13, 345, 10.1007/s10989-007-9090-3 · DOI · Paper page
  33. Krzysiak, 2007, Combinatorial modulation of protein prenylation, ACS Chem. Biol., 2, 385, 10.1021/cb700062b · DOI
  34. Wang, 2014, Rapid analysis of protein farnesyltransferase substrate specificity using peptide libraries and isoprenoid diphosphate analogues, ACS Chem. Biol., 9, 1726, 10.1021/cb5002312 · DOI
  35. Jennings, 2016, Analogs of farnesyl diphosphate alter CaaX substrate specificity and reactions rates of protein farnesyltransferase, Bioorg. Med. Chem. Lett., 26, 1333, 10.1016/j.bmcl.2015.12.079 · doi:10.1016/j.bmcl.2015.12.079
  36. Tong, 2005, Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells, Anal. Biochem., 336, 51, 10.1016/j.ab.2004.09.024 · doi:10.1016/j.ab.2004.09.024
  37. Jamur, 2010, Permeabilization of cell membranes, Methods Mol. Biol., 588, 63, 10.1007/978-1-59745-324-0_9 · DOI · Paper page
  38. Hofmann, 2014, A novel alkyne cholesterol to trace cellular cholesterol metabolism and localization, J. Lipid Res., 55, 583, 10.1194/jlr.D044727 · DOI
  39. Haberkant, 2013, In vivo profiling and visualization of cellular protein-lipid interactions using bifunctional fatty acids, Angew. Chem., Int. Ed., 52, 4033, 10.1002/anie.201210178 · DOI
  40. Wright, 2006, Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras, J. Lipid Res., 47, 883, 10.1194/jlr.R600004-JLR200 · DOI · Paper page
  41. Keller, 2005, Visual monitoring of post-translational lipid modifications using EGFP-GTPase probes in live cells, Methods, 37, 131, 10.1016/j.ymeth.2005.05.023 · DOI
  42. Ali, 2010, A novel statin-mediated “prenylation block-and-release” assay provides insight into the membrane targeting mechanisms of small GTPases, Biochem. Biophys. Res. Commun., 397, 34, 10.1016/j.bbrc.2010.05.045 · DOI
  43. Choy, 2001, Green fluorescent protein-tagged ras proteins for intracellular localization, Methods Enzymol., 332, 50, 10.1016/S0076-6879(01)32191-2 · doi:10.1016/s0076-6879(01)32191-2
  44. Crick, 1995, Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells, Biochem. Biophys. Res. Commun., 211, 590, 10.1006/bbrc.1995.1854 · doi:10.1006/bbrc.1995.1854
  45. Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
  46. Pompliano, 1993, Isoprenoid diphosphate utilization by recombinant human farnesyl-protein transferase - interactive binding between substrates and a preferred kinetic pathway, Biochemistry, 32, 8341, 10.1021/bi00083a038 · DOI
  47. Hougland, 2010, Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities, J. Mol. Biol., 395, 176, 10.1016/j.jmb.2009.10.038 · DOI
  48. Zaro, 2014, Chemical Reporter for Visualizing Metabolic Cross-Talk between Carbohydrate Metabolism and Protein Modification, ACS Chem. Biol., 9, 1991, 10.1021/cb5005564 · doi:10.1021/cb5005564
  49. Janda, 2012, Defective autophagy in Parkinson’s disease: role of oxidative stress, Mol. Neurobiol., 46, 639, 10.1007/s12035-012-8318-1 · DOI
  50. Pickford, 2008, The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid-β accumulation in mice, J. Clin. Invest., 118, 2190, 10.1172/JCI33585 · DOI · Paper page
  51. Rubinsztein, 2005, Autophagy and its possible roles in nervous system diseases, damage and repair, Autophagy, 1, 11, 10.4161/auto.1.1.1513 · DOI · Paper page
  52. Xing, 2012, Beclin 1 knockdown inhibits autophagic activation and prevents the secondary neurodegenerative damage in the ipsilateral thalamus following focal cerebral infarction, Autophagy, 8, 63, 10.4161/auto.8.1.18217 · DOI · Paper page
  53. Hung, 2009, Autophagy protects neuron from Abeta-induced cytotoxicity, Autophagy, 5, 502, 10.4161/auto.5.4.8096 · DOI · Paper page
  54. Wasko, 2011, Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate, J. Pharmacol. Exp. Ther., 337, 540, 10.1124/jpet.110.175521 · DOI
  55. Hooff, 2012, Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice, Mol. Neurobiol., 46, 179, 10.1007/s12035-012-8285-6 · DOI
  56. Grkovic, 2013, IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments, Oncogene, 32, 2412, 10.1038/onc.2012.264 · DOI
  57. Puustinen, 2014, CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation, J. Cell Biol., 204, 713, 10.1083/jcb.201304012 · DOI
  58. Zhang, 2013, Statins, autophagy and cancer metastasis, Int. J. Biochem. Cell Biol., 45, 745, 10.1016/j.biocel.2012.11.001 · DOI

Cited by

Metadata

Authors
Palsuledesai, C. C., Ochocki, J. D., Kuhns, M. M., Wang, Y.-C., Warmka, J. K., Chernick, D. S., Wattenberg, E. V., Li, L., Arriaga, E. A., & Distefano, M. D.
Affiliations
University of Minnesota , , , ,
Venue
ACS Chemical Biology
Published
2016-08-15
Volume
11
Issue
10
Pages
2820-2828
ISSN
  • 1554-8929
  • 1554-8937
Cited by
49
References
4
Language
en
Funders
  • National Institute on Aging (R01 AG020866, R01 AG031846)
  • National Institute of General Medical Sciences (R01 GM058842, R01 GM084152, T32 GM008347, T32-GM08700)
  • Division of Chemistry (CHE-1308655)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.